Document is current
Any future updates will be listed below
-
Authors
Subbiah, Vivek https://orcid.org/0000-0002-6064-6837
Kurzrock, Razelle https://orcid.org/0000-0003-4110-1214
- License Information
-
More Information
Article History
Received: 11 April 2025
Accepted: 14 August 2025
First Online: 10 September 2025
Competing interests
: V.S. reports research funding for clinical trials paid to the institution from AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicine, Boston Biomedical, Boston Pharmaceuticals, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharmaceuticals, Incyte, Inhibrix, Eli Lilly/Loxo Oncology, MedImmune, NanoCarrier, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche/Genentech, Takeda and Turning Point Therapeutics; consulting/advisory role (paid to institution) from AbbVie, Astex Pharmaceuticals, AstraZeneca, Bayer, Genmab, Incyte, Lilly/Loxo Oncology, Novartis, Obsidian Therapeutics, Pfizer, Pheon Therapeutics, Regeneron, Relay Therapeutics, Roche, Endeavor Biomedicines, RevMed and LabGenius therapeutics; and other consulting/advisory role/CME from Helsinn Healthcare, Jazz Pharmaceuticals, Incyte, Loxo Oncology/Lilly, Novartis, Relay Therapeutics, Daiichi Sankyo, Illumina, Bayer, Medscape, OncLive, Clinical Care Communications, PERS and Med learning group. R.K. has received research funding from Biological Dynamics, Boehringer, Caris, Datar Genomics, Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Caris, Daiichi Sankyo, EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, F. Hoffmann-La Roche AG, TD2/Volastra, Turning Point Therapeutics and X-Biotech; has an equity interest in CureMatch, CureMetrix and IDbyDNA; serves on the Board of CureMatch and CureMetrix; and is a co-founder of CureMatch. The content is solely the responsibility of the authors and does not necessarily represent the official views of the institutions.
